Clinigen

📢 Exciting news! 🎉Today, we unveiled a strengthened leadership team. A warm welcome to Jerome Charton as CEO, and Michael Mensa as CFO. #Clinigen #Leadership #PharmaServices clinigengroup.com/news/news-cont…

With an ambition to achieve net zero emissions by 2040 and a significant reduction as early as 2030, Clinigen is proud to announce its commitment to the Science Based Targets initiative (SBTi). @ScienceTargets #ScienceBasedTargets #SBTiCommitment #ClimateResponsibility

@AngadSinghChha1 Hi Angad, thanks for getting in touch. We have sent you a private message to follow up with you on your enquiry. Kind regards, Sam (Clinigen Social Media Team)

@Clinigen My son has been prescribed Orencia Abatacept (125/250mg) subcutaneous for treatment of LRBA deficiency in Mumbai India.. We are unable to procure the same here..can you please share your arrangements for delivery of the medicine in India.. Query ref 230511-000241

We are proud to sponsor an all expert session on the current issues in the optimisation of Asparaginase use in clinical practice at @SIOPEurope, Tuesday 9th May 2023. Register now to join us in Valencia. siopeurope.eu

Clinigen Insights 2023 – We are live! Should Early Access be considered an integral part of a market access strategy? Today and tomorrow, we’ll discuss this key topic and more at our Clinigen Insights event in Basel, Switzerland. #earlyaccess #managedaccess #expandedaccess

We’re pleased to announce that Clinigen has entered into an agreement to divest Lamda Laboratories to Adragos Pharma. Read the press release in full: clinigengroup.com/news/news-cont…

Final call for our free-to-attend 'Clinigen Insights Conference' with keynote speaker Tim Spector, Professor at King’s College London and co-founder of Zoe Ltd.  Have a look at the full event agenda and register to attend: bit.ly/3YnOqk1

Managed Access as part of a commercial strategy - Join our free-of-charge Clinigen Insights event to learn what needs to be considered: bit.ly/3YnOqk1 Guest speakers include Shirle Zajac, Teva, Winston Smit, BristolMyersSquibb, Chris Hoyle & Joubert Gama, Immunocore.

This #InternationalWomensDay2023 we're celebrating the incredible women at Clinigen. With 60% of our global workforce, and 60% of our Clinigen Management Academy graduates, identifying as female, we're immensely proud to provide an inclusive environment where women can thrive.

What are the recent changes in trends for #earlyaccess, and how can the updated regulatory framework in countries like France impact your #managedaccess strategy? Join us at our Clinigen Insights conference next month to learn more: bit.ly/3YnOqk1

New @DiversityRare & @RareDiseases survey aims to uncover gaps & barriers experienced by underrepresented communities. Together, we can identify and combat longstanding barriers experienced by the #RareDisease community! Participate and pass on: rarediseasediversitysurvey.org

There are over 300 million people, across the globe, living with rare diseases. That’s 5% of the worldwide population. We are supporting the day by showing our colours and highlighting the great work #rarediseaseday does in helping those across the world.  #rarediseaseday2023

We're delighted to have @timspector,  Professor at King’s College London and co-founder of Zoe Ltd., as keynote speaker at our Clinigen Insight conference in Basel next month: tim-spector.co.uk Learn more about our event and register to join: bit.ly/3YnOqk1

Together with guest speaker @mark_sheehan_ox, Associate Professor at the University of Oxford, we'll discuss how #patientengagement and ethical considerations can be integrated into the planning of a MAP. Join our Clinigen Insights conference next month: bit.ly/3YnOqk1

Clinigen Insights: Together with Florence Barkats, Chief Commercial Officer at CISIV, we will present examples of real-world data collection and how #RealWorldEvidence can add value to market access. Join our Clinigen Insights event to learn more: bit.ly/3YnOqk1

Clinigen is delighted to announce it has entered into an agreement to divest Proleukin® to Iovance Biotherapeutics for £166.7 million. The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties. Find out more: clinigengroup.com/news/news-cont…

Clinigen is excited to announce they have entered into an agreement with Accord Healthcare to initiate a Managed Access Program in Europe for relugolix (ORGOVYX®). #managedaccess #earlyaccess

Join us next year as we will be hosting our Clinigen Insights conference in Basel, Switzerland, on 23-24 March 2023, following BIO-Europe Spring 2023. Discover more and RSVP: clinigengroup.com/clinigen-insig… #managedaccess #expandedaccess

Clinigen welcomes the results of the MIROCALS study and is proud of the part one of our medicines played in this important research.

Clinigen are excited to announce the acquisition of Drug Safety Navigator, a specialist Pharmacovigilance service provider based in the US. Read the press release in full: clinigengroup.com/news/news-cont… #healthcare #clinigen #pharmacovigilance